Technologies to Advance Next Generation Anthrax Vaccines

Information

• Research Project
• 8563821

• ApplicationId

  8563821

• Core Project Number

  N01AI000000

• Full Project Number

  272201200033C-0-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  9/12/2012 - 12 years ago

• Project End Date

  11/30/2013 - 10 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2012

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• PFENEX INC

The scope of product development activities that may be addressed through this award span manufacturing and formulation process development through clinical studies, including: manufacturing, characterization and release of pilot lot cGMP material; vaccine stability testing ; conduct of non-clinical studies, e.g., Investigational New Drug (IND)-enabling toxicology studies; development, qualification and, where necessary, validation of all assays and reagents needed to support product development; and the delivery to the NIAID of 2000 doses of cGMP bulk drug substance as well as 2000 doses of cGMP final container candidate.

IC Name

• Activity

  N01

• Administering IC

  AI

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  2180144

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  855

• Ed Inst. Type

• Funding ICs

  NIAID:2180144\

• Funding Mechanism

  Non SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  PFENEX, INC.

• Organization Department

• Organization DUNS

  013603710

• Organization City

  SAN DIEGO

• Organization State

  CA

• Organization Country

  UNITED STATES

• Organization Zip Code

  921211508

• Organization District

  UNITED STATES